. 2017 Mar 31;35(1):1–15. doi: 10.3857/roj.2017.00122

Table 3.

Reirradiation outcomes of SBRT (Stereotactic Body Radiotherapy)

Author (institute)	Year	n	Site [pre-RT dose/RT interval]	Radiotherapy [median GTV volume]	Outcome	Adverse reaction
SRS/SRT
Siddiqui et al. [24] (Detroit)	2009	21	Various	13–18 Gy/1 fx or 36–48 Gy/5–8 fx two to three times weekly	RR (50%)/ 2-yr OS (14.3%)/ 2-yr	Acute G3-4 3
Siddiqui et al. [24] (Detroit)	2009	21	Various	13–18 Gy/1 fx or 36–48 Gy/5–8 fx two to three times weekly	LC (38.1%)	Late severe 3 (1 death)
CyberKnife
Himei (Okayama University)	2003	31	Various	15–40.3 Gy1–6 fx [41.2 mL]	RR (74%)	Acute mucositis 5
Himei (Okayama University)	2003	31	[60 Gy/16.3M]	15–40.3 Gy1–6 fx [41.2 mL]	RR (74%)	Acute mucositis 5
Roh (Korea)	2008	36	Various 36 cases 44 lesions	30 (18–40) Gy/3–5 fx [22.6 mL]	RR (80%)/ 2-yr OS (30.9%)/MST 16.2M	Acute G3 13
Roh (Korea)	2008	36	[70.2 Gy/24M]	30 (18–40) Gy/3–5 fx [22.6 mL]	RR (80%)/ 2-yr OS (30.9%)/MST 16.2M	Late: bone necrosis 1, soft tissue necrosis 2
Ogita (Fujimoto Hayasuzu)	2009	58	Various	31 Gy/3–8 fx [31.8 mL]	2-yr OS (29.2%)/ MST 15.5M	24 ulcer (41.4%)
Ogita (Fujimoto Hayasuzu)	2009	58	[<30 Gy/NA]	31 Gy/3–8 fx [31.8 mL]	2-yr OS (29.2%)/ MST 15.5M	24 ulcer (41.4%)
Heron et al. [25], Phase I (Pittsburgh University)	2009	25	Various	25 Gy→32 Gy→36 Gy→40 Gy→ 44 Gy 5 fx, 2 weeks [44.8 mL]	RR (17%)	No G3-4
Heron et al. [25], Phase I (Pittsburgh University)	2009	25	[64.7 Gy/13M]	25 Gy→32 Gy→36 Gy→40 Gy→ 44 Gy 5 fx, 2 weeks [44.8 mL]	RR (17%)	No G3-4
Rwigema et al. [26] (Pittsburgh University)	2010	85	Various	35 (15–44) Gy/1–5 fx, every other days [25.1 mL]	RR (68%)/ 2-yr OS (16.1%)/2-yr	No G4-5
Rwigema et al. [26] (Pittsburgh University)	2010	85	[70 Gy BED10/19.4M]	35 (15–44) Gy/1–5 fx, every other days [25.1 mL]	LC (30.7%)/ MST 11.5M	G3: taste loss 1, xerostomia 2, pain 1
Unger (Georgetown University)	2010	65	Various	30 Gy/5 fx [75 mL]	2-yr OS (33%)/MST 12M	Acute G1-3 19
Unger (Georgetown University)	2010	65	[67 Gy/26M]	30 Gy/5 fx [75 mL]	2-yr OS (30%)/2-yr LRC (41%)/MST 20M	Late G4 6 (9%)
Kodani (Kyoto Prefectural University)	2011	21	Various	30 (19.5–42) Gy/5 (3–8) fx [10 mL]	RR (61%)/2-yr OS (50%)/MST 23M	Severe late 6
Kodani (Kyoto Prefectural University)	2011	21	[60 Gy/51M]	30 (19.5–42) Gy/5 (3–8) fx [10 mL]	RR (61%)/2-yr OS (50%)/MST 23M	Severe late 6
Cengiz et al. [27] (Turkey)	2011	46	Various (6 multiple RT)	30 (18–35) Gy/5 (1–5) fx [45 mL]	RR (58%)/1-yr OS (46%)/MST 10.5M	Acute G2 6 (13.3%)
Cengiz et al. [27] (Turkey)	2011	46	[61 Gy/38M	30 (18–35) Gy/5 (1–5) fx [45 mL]	RR (58%)/1-yr OS (46%)/MST 10.5M	Acute G2 6 (13.3%)

SBRT, stereotactic body radiotherapy; RT, radiation therapy; M, months; GTV, gross tumor volume; SRS, stereotactic radiosurgery; SRT, stereotactic radiotherapy; fx, fractions; RR, response rate; LC, local control; OS, overall survival; MST, median survival time; LRC, locoregional control; G, grade.